FDA expands T-cell therapy approval for synovial sarcoma to include adolescents.

The FDA has granted full approval for Tecelera, an engineered T-cell therapy, for advanced synovial sarcoma. This expansion now includes eligible patients aged 12 and older, offering a new treatment option for adolescents and adults with this rare cancer, particularly when other therapies have failed.